Страна: Канада
Език: английски
Източник: Health Canada
METHOTREXATE (METHOTREXATE SODIUM)
PHARMASCIENCE INC
L01BA01
METHOTREXATE
10MG
SOLUTION
METHOTREXATE (METHOTREXATE SODIUM) 10MG
INTRA-ARTERIAL
0.4 ML
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0107545002; AHFS:
APPROVED
2015-03-10
PRODUCT MONOGRAPH PR METHOTREXATE INJECTION, BP 25 mg/mL methotrexate (as methotrexate sodium) Single-Use Pre-Filled Syringes Sterile ANTIMETABOLITE AND ANTIRHEUMATIC PHARMASCIENCE INC. DATE OF REVISION: 6111 Royalmount Ave., Suite # 100 November 28, 2019 Montréal, Québec H4P 2T4 Submission Control No.: 231323 _METHOTREXATE INJECTION, BP Product Monograph _ _Page 2 of 50 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................................ 3 SUMMARY PRODUCT INFORMATION .............................................................................................................. 3 INDICATIONS AND CLINICAL USE .................................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................................................... 5 ADVERSE REACTIONS ....................................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................................... 17 DOSAGE AND ADMINISTRATION.................................................................................................................... 21 OVERDOSAGE ..................................................................................................................................................... 30 ACTION AND CLINICAL PHARMACOLOGY .................................................................................................. 31 STORAGE AND STABILITY ............................................................................................................................... 34 SPECIAL HANDLING Прочетете целия документ